NTLA Shares Plunge 28.7% on Q3 Filing and Phase 1 ATTR Amyloidosis Data

Introduction

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2014, the company utilizes CRISPR/Cas9 genome-editing technology to develop in vivo and ex vivo therapies for severe genetic and life-threatening diseases.

Corporate Structure and Workforce

As of November 2025, Intellia employs between 501 and 1,000 professionals across research, development, manufacturing, and corporate functions. The public company maintains its principal laboratory and offices in Cambridge and operates a modular platform for lipid nanoparticle delivery. Intellia collaborates with several partners—including Novartis, Regeneron, Avencell, and Kyverna—to advance its pipeline and share development costs, milestones, and royalties.

Gene editing by Sangharsh Lohakare

Developments and News

On November 6, 2025, Intellia’s common shares closed at $8.78 on the NASDAQ, reflecting a 28.73% decline on a trading volume of 551,462. That day, the company filed its Form 10-Q for the quarter ended September 30, 2025, detailing continued investment in clinical programs and cash reserves. A Schedule 13G/A filed on November 4, 2025, indicates that ARK Investment Management holds 11,919,178 shares, representing 11.10% of outstanding stock.

In early November, Intellia published longer-term data from its Phase 1 trial of NTLA-2001 for ATTR amyloidosis with polyneuropathy via NEJM Group. The company also participated in the HAE International Regional Conference in Rome and hosted its annual internal symposium to highlight progress across its in vivo and ex vivo platforms.

Financial and Strategic Analysis

For the trailing twelve months, Intellia reported revenue of $52.9 million and a net loss of $480.2 million. As of September 30, 2025, it held approximately $459.7 million in cash and cash equivalents, supporting ongoing research and clinical operations. The company’s enterprise value stands at $1.84 billion, with a market capitalization near $2.19 billion. A price-to-sales ratio of 39.7 and a price-to-book ratio of 3.1 reflect the company's valuation relative to its current revenue.

Market Position and Industry Context

Intellia operates in the gene-editing sector alongside Editas Medicine and CRISPR Therapeutics, focusing on unmet medical needs including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Its proprietary lipid nanoparticle delivery system facilitates in vivo editing, while ex vivo cell engineering programs target oncology and autoimmune indications. The regulatory landscape for in vivo gene editing is complex, and ongoing funding dynamics continue to influence development timelines.

tl;dr

On November 6, 2025, NTLA shares fell 28.73% to $8.78 on volume of 551,462. The Q3 2025 Form 10-Q filed that day reported sustained R&D spending and cash reserves of $459.7 million. A Schedule 13G/A filed November 4 shows ARK Investment Management holds 11.10% of outstanding shares. Early November data in NEJM Group detailed longer-term Phase 1 results for NTLA-2001 in ATTR amyloidosis. Strategic partnerships and existing cash reserves support ongoing clinical programs, while evolving regulatory and funding conditions will shape progress into 2026.